Highest-materiality recent filing
Cytek Biosciences SVP Global Sales Philippe Busque resigns effective June 5
Philippe Busque, Ph.D., SVP Global Sales and Services, resigned effective June 5, 2026.
Cytek Q1 revenue $44.1M (+6% YoY); net loss widens to $18.9M; reaffirms FY guidance
Total revenue $44.1M (+6% YoY); service revenue $15.4M (+15%).
Cytek Q4 revenue $62.1M (+8% YoY); net loss $44.1M on $38.1M deferred tax valuation allowance
Full-year 2025 revenue $201.5M (+1% YoY); Q4 set record quarterly revenue.
Cytek sees Q4 rev $62M (+8% YoY); FY2025 rev ~$201M
Preliminary Q4 2025 revenue of ~$62M, up 8% YoY and 19% QoQ.
Cytek Q3 2025 net loss $5.5M; adjusted EBITDA $2.5M; revenue +2% to $52.3M
Total revenue $52.3M, +2% YoY; installed base 3,456 instruments (+161 units in Q3).
Cytek Q2 2025 revenue $45.6M (-2% YoY); narrows 2025 guidance to $196-205M
Revenue $45.6M, down 2% YoY; net loss $5.6M vs $10.4M loss in Q2 2024.
Cytek director nominee Deborah Neff fails election; other proposals pass
Deborah Neff received 33.8M votes for vs. 48.2M withheld, failing to be elected as Class I director.
Cytek Q1 revenue down 7.6% to $41.5M; net loss widens; FY2025 guidance reduced
Revenue $41.5M (-7.6% YoY); gross margin 49% vs 51%; net loss $11.4M vs $6.2M loss prior year.
Cytek Biosciences Q4 rev $57.5M (-1.3%); FY24 net loss $6.0M; guides FY25 rev $204-212M
Full year 2024 revenue $200.5M (+3.9% YoY); Q4 revenue $57.5M (-1.3% YoY, +1.4% constant currency).
Cytek Biosciences expects FY2024 revenue $200-201M, 4% growth; Q4 rev up 11-13% QoQ
Full-year 2024 revenue expected $200-201M, up 4% from $193M in 2023; ~$1M negative FX impact.
Cytek Q3 revenue $51.5M (+7% YoY); net income $0.9M vs loss year ago
Total revenue $51.5M, up 7% vs Q3 2023; year-to-date revenue $143.0M, up 6%.
Cytek Biosciences COO Paul Christopher Williams resigns effective Sept 27, 2024
COO Paul Christopher Williams resigned on Sept 9, 2024, effective Sept 27, 2024, to pursue another career opportunity.
Cytek Q2 revenue $46.6M, -6% YoY; net loss widens to $10.4M
Revenue $46.6M (-6% YoY, +4% QoQ); GAAP gross margin 55% (adjusted 58%).
Cytek Biosciences 2024 annual meeting results: all proposals approved by shareholders
Elected Wenbin Jiang and Michael Holder as Class III directors with 64.2M and 70.3M votes for, respectively.
Cytek Q1 revenue $44.9M (+21% YoY); organic revenue up 11%; reaffirms 2024 guidance
Total revenue $44.9M, +21% YoY; organic revenue (ex-Luminex) $37.3M, +11%.
On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc. (the “Company”), effective as of June 5, 2026, to pursue another career opportunity.
On September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of Cytek Biosciences, Inc. (the “Company”), effective as of September 27, 2024, to pursue another career opportunity.
Max materiality 0.75 · Median 0.65 · Most common event earnings